Invion Limited

Invion Limited Notification of Security Consolidation or Split

Invion Limited's (ASX: IVX) (“Invion” or the “Company”) notification of security consolidation or split.


ANNOUNCEMENT SUMMARY


Applicable security for the reorganisation

IVX ORDINARY FULLY PAID

IVXAX OPTION EXPIRING 22-OCT-2024 EX $0.0177

IVXAZ OPTION EXPIRING 31-OCT-2024 EX $0.0106

IVXAAK OPTION EXPIRING 01-MAY-2026 EX $0.01

IVXAAJ OPTION EXPIRING 13-JAN-2026 EX NIL

IVXAAC OPTION EXPIRING 23-SEP-2025 EX $0.017

IVXAAI OPTION EXPIRING 17-NOV-2026 EX NIL

IVXAAM OPTION EXPIRING 28-NOV-2026 EX $0.01

IVXAAL OPTION EXPIRING 01-DEC-2026 EX $0.01

Announcement Type

New Announcement

Date of this announcement

15/10/2024

Reorganisation type

Security consolidation

Trading in the post consolidation or split +securities commences on a deferred settlement basis

20/11/2024

Record Date

21/11/2024

Issue Date

28/11/2024

Click here for the full ASX Release

This article includes content from Invion Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

IVX:AU
Invion Limited

Invion Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Invion Limited

Invion Limited

Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases

Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases Keep Reading...
Hanlim & Korean Government Fund Pathway to Clinical Trial

Hanlim & Korean Government Fund Pathway to Clinical Trial

Invion Limited (IVX:AU) has announced Hanlim & Korean Government Fund Pathway to Clinical TrialDownload the PDF here. Keep Reading...
Invion Secures Expanded Photosoft Global Exclusive License

Invion Secures Expanded Photosoft Global Exclusive License

Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
Appendix 4C and Quarterly Activities Report - September 2025

Appendix 4C and Quarterly Activities Report - September 2025

Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
Funded Collaboration Agreement with Protect Animal Health

Funded Collaboration Agreement with Protect Animal Health

Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
Repayment of Lind Facility with Successful Capital Raise

Repayment of Lind Facility with Successful Capital Raise

Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks (Updated January 2026)

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks (Updated January 2026)

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
Various colorful pills and tablets scattered from a brown bottle on a blue background.

Pharma Market Forecast: Top Trends for Pharma in 2026

The pharmaceutical sector is entering 2026 at a critical juncture. While recent initial public offering (IPO) performance has been stellar, with pharma firms claiming five of the top 10 IPO returns this year, the outlook next year is dominated by significant investment headwinds. Large,... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Invion Limited

Invion Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News